"Without the funding and support from The North West Fund our products would not be nearly as developed as they are now."
eligibility checklist

Have a question?

Visit our list of Frequently Asked Questions

Read more
eligibility checklist

What type of finance do I need?

Our online eligibility checklist helps you see which type of finance might be right for your business.

Read more

Zilico develops system for ‘real time’ cervical cancer screening results

Fund: Biomedical

Manchester-based Zilico Ltd has developed a new system to provide 'real time' results for women within the cervical cancer programme after receiving funding from The North West Fund for Biomedical...

The system, which consists of a portable hand-held device, a single use disposable sleeve and docking station, removes weeks of waiting for results.

The first application of the device, called ZedScan, detects changes in tissues as they progress from normal to pre-cancerous and then to cancerous by measuring the resistivity of the cells.

Zilico will use recent funding from The North West Fund for Biomedical to establish a route to market throughout Europe and other high-growth markets as it continues to develop further products. The business is seeking to hire three more people over the next six months.

In October 2012, Zilico secured £750,000 of funding from various investors including The North West Fund for Biomedical, managed by Spark Impact, in addition to £1m that was announced in June 2012.

Chief executive of Zilico, Sameer Kothari, said: "Without the funding and support from The North West Fund our products would not be nearly as developed as they are now. ZedScan is becoming well known in the medical community and we look forward to launching the product on the international market.

"The fund managers are very experienced in the healthcare sector so they understand the market and they understand our product offering. They have helped us navigate the steps to ensure a medical company is commercially successful."

Penny Attridge, senior investment director at SPARK Impact, which manages The North West Fund for Biomedical, said: "As an investor, Zilico has great commercial appeal. It is a convenient and simple device that has the potential to significantly improve women's healthcare."

Zilico was originally spun out from the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust. Cervical cancer affects around 500,000 women worldwide each year and is responsible for 300,000 deaths.


For more information about how you may be able to access funding for your biomedical business please visit /funds/biomedical

Back to article list